PMI, N = 39, N (%) | Global Fund N = 107, N (%) | World Bank N = 13, N (%) | Total, N = 159, N (%) | |
---|---|---|---|---|
WHO Region | ||||
Americas | 0 (0) | 8 (7.5) | 0 (0) | 8 (5.0) |
Africa | 37 (94.9) | 64 | 11 | |
Eastern Mediterranean | 0 (0) | 1 (0.9) | 1 (7.7) | 2 (1.3) |
East Asia and Pacific | 2 (5.1) | 16 (15.0) | 1 (7.7) | 19 (12.0) |
South Asia | 0 (0) | 13 (12.2) | 0 (0) | 13 (8.2) |
Europe | 0 (0) | 5 (4.7) | 0 (0) | 5 (3.1) |
World Bank income group | ||||
Upper-middle income | 4 (10.3) | 8 (7.5) | 0 (0) | 12 (7.6%) |
Lower-middle income | 8 (20.5) | 45 (42.1) | 3 (23.1) | 56 (35.2%) |
Low income | 27 (69.2) | 54 (50.5) | 10 (76.9) | 91 (57.2%) |
Amount of granta | 12.7 million USD (3–70 million USD) | 30.0 million USD (0.6–284 million USD) | 82.0 million USD (46–500 million USD) | 33.3 million USD (0.6–500 million USD) |
Pharmacovigilance mentions | ||||
Grant mentions pharmacovigilance | 21 (53.9) | 2 (1.9) | 0 (0) | 23 (14.5) |
Grant provides budget line for pharmacovigilance | 21 (53.9) | 16 (15.0) | 0 (0) | 37 (23.3) |